Kornimate/medical-research-clean huggingface dataset:
impact evaluation of a social franchise model for improving infant and young child feeding and child nutrition in vietnam

Conditions: Child Nutrition; Stunting; Exclusive Breastfeeding; Complementary Feeding

Summary: alive \& thrive is an initiative that aims to improve infant and young child feeding practices and reduce childhood stunting. in vietnam, alive \& thrive's primary intervention is implemented through a social franchise linked with the government's health system. the impact evaluation is conducted using a cluster-randomized design in which 20 commune health centers (chc) were assigned to the social franchise model, and 20 chc were assigned to routine government services. repeated cross-sectional baseline and endline surveys will be used to assess the public health impact of this intervention. the baseline was in 2010 and an endline survey in the same communities will be conducted in 2014. mixed methods process evaluation will be conducted in 2011, 2012 and 2013 to study the pathways through which the program impact is achieved.

link provided to journal manuscript describing design of evaluation provides additional detail: http://fnb.sagepub.com/content/34/3_suppl2/s195.full.pdf

Eligibility criteria:
inclusion criteria: * children 0-60 months of age exclusion criteria: * none

Keywords: child nutrition stunting exclusive breastfeeding complementary feeding social franchise mass media counseling facility-based
angiographie and oct in macula and retinal diseases

Conditions: Macular Edema

Summary: the purpose of this study is to investigate the morphological and angiological retinal changes in different macular diseases.

recently, a new generation of oct devices relying on spectral domain technology (sd-oct) has been introduced and allows for higher-resolution imaging. based on this technology we can identify variable changes at the retinal surface such as, retinal thickening with cyst formation, swelling in the inner and outer nuclear layers and subretinal fluid. the introduction of an eye-tracking mode has allowed a better insight into the development of retinal morphologic changes the aim of this study was to investigate the incidence and structural morphology of pcme after successful uncomplicated cataract surgery in patients with previous pars plana vitrectomy (ppv) and indocyanine green-assisted peeling of an epiretinal membrane and the internal limiting membrane (ilm).

Eligibility criteria:
inclusion criteria: * previous 23-gauge ppv and ilm peeling exclusion criteria: * history of branch retinal vein occlusion * central retinal vein occlusion * wet macular degeneration * diabetic retinopathy * uveitis or other inflammatory eye disease.

Keywords: vitrectomy cataract macular edema
fat grafting in skin-grafted deep burn scars

Conditions: Burn Scar

Summary: fat grafting in human skin-grafted immature burn scars histological, clinical and photographic follow-up

objective: a randomised clinical trial was performed to determine the effect of autologous fat grafting on scar formation in early skin-grafted deep burn wounds. methods: included patients received split-thickness skin grafting procedures for deep burn wounds less than 3 months ago. a homogenous scar area in each patient was divided into two equal parts. one part was treated with transcutaneous sharp needle autologous fat grafting, the adjacent part with transcutaneous saline injection as control. results were evaluated by clinical assessment with scar scale questionnaires, histological examination, and objective scar assessment with cutometer, mexameter, tewameter and corneometer.

Eligibility criteria:
inclusion criteria: * early skin-grafted deep burn scars * otherwise healthy exclusion criteria: * concomitant disease

Keywords: burn scar fat grafting
impact of a targeted 8-week exercise program on pain measures and isokinetic muscle strength in females with patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain syndrome (pfps) is condition characterized by anterior knee pain that predominantly affects young and physically active females. the etiology of pfps is multifactorial, involving biomechanical, muscular, and neuromuscular factors that contribute to altered patellar tracking and increased pain sensitivity.

this study will employ a randomized controlled trial (rct) design to evaluate the effects of a targeted 8-week exercise program on pain measures and isokinetic muscle strength in females with pfps. thirty female patients diagnosed with pfps will be recruited based on predefined inclusion and exclusion criteria. participants will be randomly assigned into two groups: an intervention group receiving the targeted exercise program, and a control group will not receive any intervention.the intervention group will undergo a supervised, structured exercise program lasting 8 weeks, focusing on strengthening the hip and knee muscles, improving neuromuscular control, and addressing pain sensitivity. sessions will be conducted multiple times per week under professional supervision. outcome measures will include pain measures, assessed through validated tools such as pressure pain threshold and pain intensity measured by vas scale and isokinetic muscle strength of knee and hip muscles, measured by isokinetic dynamometry at the biodex isokinetic laboratory at the faculty of physical therapy, cairo university.

Eligibility criteria:
inclusion criteria: eligible participants will present with clinically diagnosed anterior knee pain exacerbated by activities such as stair climbing, squatting, or prolonged sitting, with a pain duration of at least three months to ensure chronicity. all participants will possess adequate intellectual and cognitive abilities to comprehend and follow exercise instructions, and they will provide informed consent prior to enrollment. exclusion criteria: exclusion criteria will include any history of knee surgery or trauma within the past year, presence of other knee pathologies such as ligament injuries or osteoarthritis, neurological or systemic disorders affecting lower limb function, pregnancy, contraindications to exercise, or current involvement in other physical therapy or structured exercise programs targeting the knee.

Keywords: patellofemoral pain syndrome weight-bearing pain isokinetic strength
dexmedetomidine versus standard clinical practice during non invasive mechanical ventilation

Conditions: Acute Respiratory Failure

Summary: this study compare the effectiveness of dexmedetomidine as a sedative drug during niv and the different strategies routinely used in patients with arf of different aetiologies. efficacy will be assessed based on absence of intubation, short term prognosis, and occurrence of medical complications.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * competent or with legal representative able to sign inform consent. * reversible arf secondary to heart failure, copd exacerbation, pneumonia, or at risk of pot-extubation failure\* who meet the criteria for starting niv. * signs and symptoms of respiratory distress or * moderate to severe dyspnoea, grater than usual and/or * respiratory rate greater than 25 in copd or greater than 30 in hypoxemic arf and/or * use of accessory muscles and/or paradoxical breathing and/or * hypercapnic encephalopathy * and changes in gas exchange * paco2\>45 mmhg, ph\<7.35 and/or * pao2/fio2 between 300 and 150. \*patients at risk of post-extubation failure: patients who meet at least one of the following criteria. * impaired consciousness. * age over 65 years * heart failure with ef \>30% * severe disease with an acute physiology and chronic health evaluation (apsche) score \>12. * protracted weaning before extubation exclusion criteria: * respiratory arrest, direct indication of oti and imv. * severe unstable comorbidity (myocardial ischemia with ejection fraction \ 0.5 mcg/kg/min and/or dobutamine\>10 mcg/kg/min). * inability to protect the airway: bronchial aspiration. * fixed upper airway obstruction. * tracheostomy. * undrained pneumothorax. * severe agitation or lack of collaboration of the patient despite medication administered. * facial burns or trauma. * facial surgery or anatomical changes which prevent mask fitting. * hypersensitivity to the active substance or to any of the excipients listed in section 6.1. * allergy to eggs, soya, or peanuts. * hr\< 50 bpm not induced by beta- blockers. * advanced heart block (grade 2 or 3) unless paced. * acute cerebrovascular conditions. * increased intracranial pressure. * closed angle glaucoma. * myasthenia gravis. * concurrent use of cyp3a4 inhibitors (amprenavir, atazanavir, or ritonavir). * refuse to participate in the trial. * pregnant or nursing patients.
del nido cardioplegia randomized trial

Conditions: Cardiac Perfusion

Summary: the use of a modified depolarizing cardioplegia solution in adult cardiac surgery would allow for prolonged re-dosing intervals while providing equivalent myocardial protection. the use of del nido solution has been used extensively in congenital heart surgery for over 25 years. the primary objective is to determine whether expanding this technique to adult cardiac surgery will confer significant benefits in both surgical workflow and patient clinical outcome. the investigators hypotheses with regard to the del nido solution will demonstrate (1) a non-inferior delivery to the current blood-based cardioplegia strategy in functional recovery or clinical outcome, and (2) superior delivery to the current blood-based cardioplegia strategy in cost analyses.

this prospective randomized controlled trial is designed for adult patients between the ages of 19-79 presenting for isolated cabg or single valve surgery, with or without cabg, requiring the use of cardio-pulmonary bypass (cpb). patients with previous cardiac surgery or requiring mechanical and pharmacologic support will be excluded from the study. subjects randomized to the intervention group will receive del nido cardioplegia solution during the aortic cross clamp period. the control group will receive whole-blood cardioplegia according to the inova fairfax adult cardioplegia protocol. primary outcomes include clinical indicators for myocardial preservation such as serum troponin levels and the return of spontaneous rhythm. surrogate primary endpoints for myocardial protection include the requirement for inotropic support and the need for defibrillation after coronary reperfusion. secondary endpoints include post-operative clinical outcomes, duration of the aortic cross clamp period, and total expenses incurred during the patient length of stay. the investigators will conduct non-inferiority analyses to examine the effect of cardioplegia treatment arm on clinical outcomes and complications. analyses of binary outcomes will use a 5% non-inferiority margin and analyses of continuous outcomes will use a 10% non-inferiority margin.

Eligibility criteria:
inclusion criteria: * subjects able to receive and provide informed consent * elective surgical procedures requiring cpb and myocardial arrest * isolated coronary artery bypass graft (cabg) surgery or single valve surgery, with or without cabg exclusion criteria: * previous cardiac surgery * patients with preoperative inotropic pharmacological support * patients on preoperative mechanical circulatory support * patients with an implanted pacemaker or implantable cardioverter defibrillator * patients with non-isolated cabg or other non-cabg procedures with single valve surgery

Keywords: cabg valve surgery cardioplegia heart surgery cardiac surgery cardio-pulmonary bypass myocardial arrest coronary artery bypass graft cpb
investigation of immediate, short and long term effects of mulligan mobilization with movement techniques in nonspesific chronic low back pain

Conditions: Chronic Low Back Pain

Summary: introduction: although the effectiveness of many mobilization methods in chronic low back pain (clbp) was shown, these effects were not monitored in the long term. the aim of this study was to identify the immediate, short and long-term effects of mulligan mobilization with movement (mwm) in terms of pain, range of motion (rom), flexibility, endurance, functionality and disabilities in patients with clbp. methods: the study was designed in randomized-placebo controlled with 36 people randomly distributed into 2 groups. sustained natural apophyseal glide (snag) was applied to the lumbar region, straight leg raise (slr) with traction to the hip, and internal rotational mobilization techniques and home exercise program were applied in group 1 (n=19); and the same techniques were applied as sham mobilization in group 2 (n=17). the evaluations were made as post-intervention for immediate effect, and were also made at the 5th week, 3rd month, and 6th months for short and long-term effect. evaluation was also made for pain in 12th month.


Eligibility criteria:
inclusion criteria: * having 3 months' continuous or intermittent lbp symptoms, without leg pain above the knee * pain at vas \> 3/10, * back pain increased by active lumbar flexion movement exclusion criteria: * confirmed nerve root compression * neurological symptoms * lumbar spine stenosis * back surgery history * chronic pain syndrome * lbp from fracture * infection * visceral disease * pregnancy * major clinical depression * cauda equina syndrome * significant osteoporosis.
spyglass versus eswl for large common bile duct stones

Conditions: Choledocholithiasis; Common Bile Duct Calculi

Summary: overall stone clearance with endoscopic retrograde cholangiopancreatography (ercp) for choledocholithiasis is a big problem, especially for stones with a diameter greater than 3cm. after ercp failure, surgery was the option but patients not suitable for surgery were treated through stenting but had to undergo multiple ercps and show a success rate of only 44-96%. recently, choledochoscopic laser, electrohydraulic lithotripsy, spyglass, or extracorporeal shock wave lithotripsy (eswl) have been applied for the treatment of huge bile duct stones. the present study aims to compare the efficacy and safety outcomes of spyglass direct vision lithotripsy and eswl procedures for the removal of large bile duct stones.

eswl was first used for the removal of renal calculi and ureteral calculi however, now a day is being used for biliary calculi. it has the advantages of simple operation, low cost, and higher safety. recent studies show that the procedure time for eswl is also shorter and the utilization rate of mechanical lithotripsy was effectively reduced with fewer complications. but it is difficult for eswl to break the stones larger than 3cm into small pieces. so spyglass-guided laser lithotripsy is used. spyglass has been used in clinics for more than ten years. recently, a study reported difficult bile duct stones that were treated with spyglass-guided laser lithotripsy that shows promising results. compared with laser lithotripsy under x-ray monitoring, there is no significant difference in stone removal rate and complication rate between the two methods. however, the effect of lithotripsy under spyglass direct vision is better, which can break large stones into smaller pieces, thus making it easier to take stones. the investigators conducted the current study to compare the therapeutic outcome and complications between spyglass direct vision lithotripsy and eswl procedures for the removal of large bile duct stones

Eligibility criteria:
inclusion criteria: * large bile duct stones (≥10 mm) exclusion criteria: * pregnancy * refusal of written informed consent * patients with benign or malignant biliary stricture * contraindications to ercp exist * complicated with acute pancreatitis or acute cholangitis * coagulation dysfunction#thrombocytopenia * patients after gastrointestinal reconstruction

Keywords: choledocholithiasis; spyglass; eswl;ercp
phase 3 study - safety and efficacy of ptk 0796 in patients with complicated skin and skin structure infection (csssi)

Conditions: Skin Structures and Soft Tissue Infections

Summary: a phase iii trial to demonstrate the safety and efficacy of ptk 0796 in the treatment of complicated skin and skin structure infections (csssi).

the pharmacologic profile of ptk 0796 in humans suggests that it has the potential to be used safely and effectively for this indication. data from in vitro and animal studies support this hypothesis. in ptk 0796-cssi-0805 the safety and efficacy of ptk 0796 in the treatment of csssi will be compared to an antibiotic approved for this indication by the fda. initial treatment will be administered intravenously with the option for subsequent oral treatment.

Eligibility criteria:
inclusion criteria: * has and acute complicated skin and skin structure infection with findings of systemic inflammatory response * patients, ages 18 years or older * is expected to require greater than or equal to 4 days antibiotic therapy * female patients must not be pregnant at the time of enrollment and must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug exclusion criteria: * has received an investigational drug within the past 1 month * has been previously enrolled in this protocol * has received \>48hr of potentially effective systemic antibiotic immediately prior to study drug * is nursing

Keywords: cssi abscess would cellulitis complicated skin and skin structure infections (csssi)
a study of ly900014 in participants with type 1 diabetes on insulin injection therapy

Conditions: Diabetes Mellitus, Type 1

Summary: the study will be conducted in participants with type1 diabetes on insulin injection therapy to investigate how the body processes ly900014 and the effect of ly900014 on blood sugar levels. side effects and tolerability will be documented. the study will be conducted in two parts (part a and part b) to achieve its objectives. participants are expected to enroll in both parts.


Eligibility criteria:
inclusion criteria: * are male or female participants with type 1 diabetes mellitus (t1dm) on a stable multiple daily injection regimen with a short-acting as well as a long-acting insulin * have a body mass index (bmi) ranging from 18.5 to 33.0 kilogram per square meter (kg/m²), inclusive, at screening * have blood pressure, pulse rate, electrocardiogram (ecg), blood and urine laboratory test results acceptable for the study * have had no episodes of severe hypoglycemia in the past 6 months (requiring assistance in treatment by a second party) * have venous access sufficient to allow for blood sampling * have provided written consent and are willing to follow study procedures and commit to the study duration exclusion criteria: * are currently enrolled, or have participated within the last 30 days, in a clinical trial or any other type of medical research judged to be incompatible with this study * have previously completed or withdrawn from this study * have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate in the study * had blood loss of more than 500 milliliters (ml) within the last month * are treated with a continuous subcutaneous insulin infusion (insulin pump)
mek inhibitor pd-325901 to treat advanced breast cancer, colon cancer, and melanoma.

Conditions: Melanoma; Colonic Neoplasms; Breast Neoplasms

Summary: mek is a critical member of the mapk pathway involved in growth and survival of cancer cells. pd-325901 is a new drug designed to block this pathway and kill cancer cells. the purpose of this study is to study the effectiveness of pd-325901 in patients with colon cancer, breast cancer, and melanoma. pd-325901 will be given by mouth as a pill twice a day, ct scans will be done and biopsies will be taken of a tumor before and once during treatment to measure the effects of the drug. blood samples will be taken to measure the amount of drug in the blood.

the study prematurely discontinued on march 15, 2007 due to a safety concern, specifically ocular and neurological toxicity presented at 10 mg twice-a-day and higher doses.

Eligibility criteria:
inclusion criteria: * age \>= 18 years old * tumor accessible for biopsy and willingness to undergo baseline and 1 post treatment biopsy * biopsiable, histologically or cytologically confirmed metastatic or inoperable breast cancer, colon cancer, or melanoma. prior treatment requirement : i) no more than 2 prior cytotoxic chemotherapy regimens for metastatic disease for patients with breast or colon cancers; ii) no prio cytotoxic therapy for patients with melanoma, or iii) measurable lesion (s) that have not been irradiated. * adequate renal, liver, and bone marrow function, determined within 2 weeks prior to the first treatment, defined as the following: serum creatinine \ 1500/ul; and platelet \>100,000/ul * hemoglobin \>9.0 g/dl. treatment with transfusions or erythropoietin to elevate the hemoglobin level for eligibility purposes is not permitted. patients must have discontinued erythropoietin at least 2 weeks prior to the first dose of study medication * serum calcium \<1 x uln and phosphorus \<1 x uln * patients having reproductive potential must use adequate method of birth control. patients may not be pregnant or breastfeeding. * ecog status of 0,1, or 2. * must be able to swallow intact study medication and have no gastrointestinal disorders that may affect absorption of the drug * must be able to follow instructions or protocol specified procedures, or have a daily care giver who will be responsible for administering study medication. * must be able to give written informed consent. exclusion criteria: * no parathyroid disorder or history of malignancy associated hypercalcemia * no ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks; no immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within prior 2 weeks * no concurrent serious infection or life-threatening illness (unrelated to tumor) * no history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years * no untreated brain metastases.